RA-18C3

DRUG2 trials

Sponsors

Janssen Research & Development, LLC

Conditions

Acne VulgarisPsoriasis

Phase 2

Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis

CompletedNCT01384630

Janssen Research & Development, LLCPsoriasis

Start: 2011-09-30End: 2012-08-31Updated: 2025-03-30

Phase II Trial of RA-18C3 in Subjects With Moderate to Severe Acne Vulgaris

CompletedNCT01474798

Janssen Research & Development, LLCAcne Vulgaris

Start: 2012-02-29End: 2012-12-31Updated: 2025-03-30